• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 514870 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414763737 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414763737 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of United Therapeutics Under Pressure, Down 2.1%

Published on Mon, 06/10/2013 - 10:55
By Robert Cotter

United Therapeutics (NASDAQ:UTHR) is one of today's biggest movers, down 2.1% to $65.57. The Dow is trading fractionally higher to 15,261 and the S&P is currently trading fractionally higher to 1,645.

United Therapeutics (NASDAQ:UTHR) is currently priced 10.4% above its average consensus analyst price target of $58.78. The stock should discover initial support at its 50-day moving average (MA) of $64.26 and subsequent support at its 200-day MA of $57.05.

United Therapeutics share prices have moved between a 52-week high of $70.74 and a 52-week low of $36.55 and are now trading 79% above that low price at $65.57 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has advanced 0.7%.

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Cowen and Company Made the Right Call, D...

One week ago Digital Realty Trust (NYSE:DLR) was upgraded from Underperform to Market P ...

Education Realty Trust In Retrospect: Sh...

MLV & Co. upgraded Education Realty Trust (NYSE:EDR) from Hold to Buy a week ago. The ...

NCR Up 8.9% Since Goldman Sachs Upgraded...

One week ago NCR (NYSE:NCR) was upgraded from Sell to Neutral at Goldman Sachs. NCR sh ...

Argus Research's Rating Change Only Had ...

A week ago, Argus Research upgraded Nabors Industries from Hold to Buy. Nabors Industr ...

Kinder Morgan Energy Partners In Retrosp...

One week ago Kinder Morgan Energy Partners (NYSE:KMP) was downgraded from Buy to Hold a ...

Analyst Rating In Review: American Eagle...

American Eagle Outfitters was downgraded from Buy to Neutral by Goldman Sachs one week ...

Brandywine Realty Trust Up 1.5% Since St...

A week ago, Stifel upgraded Brandywine Realty Trust from Hold to Buy. The shares close ...

Analyst Rating In Review: Brandywine Rea...

Stifel upgraded Brandywine Realty Trust (NYSE:BDN) from Hold to Buy a week ago. The st ...